Ligand Pharmaceuticals reported $78.75M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.4B 300M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 450.82M 375.59M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Enviri Corporation USD 555M 19.81M Dec/2025
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 524.42M 98.93M Sep/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 151.75M 1.43M Sep/2026